SCHEMBL24173573

SCHEMBL24173573

O=C(Cc1ccccc1Cl)Nc1cnnc(Nc2ccc(F)c(F)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNJ5 P48544 6/20 0.50
▸ KCNJ3 P48549 6/20 0.50
▸ CLK2 P49760 1/20 0.47
▸ PRKX P51817 1/20 0.47
▸ CAMK2D Q13557 1/20 0.47
▸ PKN2 Q16513 1/20 0.47
▸ CLK4 Q9HAZ1 1/20 0.47
▸ STK17A Q9UEE5 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ KCNJ6 P48051 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ ROCK2 O75116 3/20 0.42
▸ ROCK1 Q13464 2/20 0.42
▸ ANO1 Q5XXA6 2/20 0.42
▸ NR1I2 O75469 1/20 0.42
▸ P2RX4 Q99571 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30285771 1.00 KCNJ5 (0.50) KCNJ5KCNJ3CLK2PRKXCAMK2D
SCHEMBL26186450 0.89 KCNJ5 (0.50) KCNJ5KCNJ3CLK2PRKXCAMK2D
SCHEMBL30285528 0.89 KCNJ5 (0.50) KCNJ5KCNJ3CLK2PRKXCAMK2D
SCHEMBL30285782 0.89 ANO1 (0.46) KCNJ5KCNJ3CLK2PRKXCAMK2D
SCHEMBL26186459 0.89 ROCK2 (0.45) ALDH1A1HTTROCK2P2RX4MAPT
SCHEMBL26186458 0.89 ANO1 (0.46) KCNJ5KCNJ3CLK2PRKXCAMK2D
SCHEMBL30285764 0.89 ROCK2 (0.45) ALDH1A1HTTROCK2P2RX4MAPT
SCHEMBL24173574 0.88 MAPT (0.49) HTTROCK2P2RX4MAPTLMNA
SCHEMBL30285698 0.88 MAPT (0.49) HTTROCK2P2RX4MAPTLMNA
SCHEMBL30285655 0.88 KCNJ5 (0.53) KCNJ5KCNJ3CLK2PRKXCAMK2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115996911-A Substituted N-phenylacetamides having P2X4 receptor antagonistic activity 拜耳公司 2023-04-21 — — CN claimed
US-20230270729-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2023-08-31 — — US disclosed
US-20230270729-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2023-08-31 — — US disclosed
US-20230257351-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2023-08-17 — — US disclosed
US-20230257351-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2023-08-17 — — US disclosed
CN-115996911-A Substituted N-phenylacetamides having P2X4 receptor antagonistic activity 拜耳公司 2023-04-21 — — CN disclosed
WO-2022002859-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2022-01-06 — — WO disclosed
WO-2022002860-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2022-01-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257351-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY P2RX2, P2RX5, P2RX3 KCNJ5 452/4885KCNJ3 610/4885CLK2 2527/4885
US-20230270729-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS P2RX2, P2RX4, P2RX5 KCNJ5 2411/4885KCNJ3 2969/4885CLK2 2207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback